These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15037110)

  • 1. Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment.
    Stjernschantz J
    Exp Eye Res; 2004 Apr; 78(4):759-66. PubMed ID: 15037110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
    Stjernschantz J; Selén G; Astin M; Resul B
    Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment.
    Stjernschantz J
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():63-8. PubMed ID: 7732906
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
    Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
    Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect.
    Bito LZ
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S1-14. PubMed ID: 9154271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
    Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
    Bioorg Med Chem; 2009 Jan; 17(2):576-84. PubMed ID: 19101156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
    Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
    Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age on the development of a latanoprost-induced increase in iris pigmentation.
    Arranz-Marquez E; Teus MA
    Ophthalmology; 2007 Jul; 114(7):1255-8. PubMed ID: 17306877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease.
    Lütjen-Drecoll E
    Exp Eye Res; 2005 Jul; 81(1):1-4. PubMed ID: 15978248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences.
    Bean GW; Camras CB
    Surv Ophthalmol; 2008 Nov; 53 Suppl1():S69-84. PubMed ID: 19038626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.
    Stjernschantz JW
    Invest Ophthalmol Vis Sci; 2001 May; 42(6):1134-45. PubMed ID: 11328719
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased iris pigment in a child due to latanoprost.
    Brown SM
    Arch Ophthalmol; 1998 Dec; 116(12):1683-4. PubMed ID: 9869807
    [No Abstract]   [Full Text] [Related]  

  • 15. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
    Wistrand PJ; Stjernschantz J; Olsson K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides.
    Martínez A; Sánchez M
    Curr Med Res Opin; 2007 Mar; 23(3):595-9. PubMed ID: 17355740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Latanoprost--a new prostaglandin F2 alpha analog in therapy of glaucoma--an overview].
    Erb C; Messerli J; Flammer J
    Klin Monbl Augenheilkd; 1998 Jan; 212(1):2-12. PubMed ID: 9541888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I; Pfeiffer N; Cracknell KP; Appleton P
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin postscript: a personal reflection.
    Bito LZ
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S231. PubMed ID: 12204719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandins in the eye: Function, expression, and roles in glaucoma.
    Doucette LP; Walter MA
    Ophthalmic Genet; 2017; 38(2):108-116. PubMed ID: 27070211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.